The unblinding of phase 3 trial data of SynCore Biotechnology Co Ltd’s (杏國新藥) newly developed pancreatic cancer drug SB05PC showed no statistical significance when compared with the control group, the drugmaker said yesterday.
SB05PC is designed to prolong patients’ lives, and the trial ended once all participants had passed away, the company said.
The trials tested whether people taking the drug would on average live significantly longer than those in the control group, it added.
Photo: CNA
The trials tested for overall survival time — the time the patient survives from the beginning of treatment — and progression-free survival time — the time the patient’s cancer does not worsen from the beginning of treatment, it said.
The median overall survival time for the 108 participants treated with SB05PC was 226 days, while their median progression-free survival time was 113 days.
Meanwhile, the median overall survival time of the 100 patients in the control group was 209 days, while their median progression-free survival time was 110 days, the drugmaker said.
“The difference between the two groups was not statistically significant,” Tim Lee (李志文), chairman of the drugmaker’s parent company Sinphar Pharmaceutical Co Ltd (杏輝醫藥), told a news conference in Taipei.
Other secondary gauges, such as disease control rate, objective response, rate and duration of response also did not show statistical significance, the company said.
The disease control rate averaged 59.38 percent in the treatment group, compared with 48.86 percent in the control group; the objective response rate was 11.46 percent in the treatment group, compared with 6.82 percent in the control group; and response to the drug averaged 4.1 months in the treatment group, compared with 5.6 months in the control group, it said.
SB05PC was developed as a second-line treatment to be combined with chemotherapy drug gemcitabine for patients who do not respond well to first-line drug Folfirinox, SynCore said.
Trail participants either received SB05PC in combination with gemcitabine, or only gemcitabine in the control group, it said.
Although no statistical significance, which would allow SynCore to seek approval for the treatment, was found, the trials were meaningful, as it would base the further development of SB05PC on the results, Lee said.
Phase 3 trials were conducted in seven countries — Taiwan, the US, France, Hungary, Israel, Russia and South Korea — and some populations seemed to react better to the drug, Lee said.
“It was a valuable experience, and we also learned how to be more exact in deciding the development direction of a new drug. This experience is an intangible asset,” Lee said.
SynCore has been developing SB05PC for six years, investing NT$2 billion (US$71.65 million) in the treatment, Lee said, adding that Sinphar funded the project with NT$1.77 billion.
After ending the project, Sinphar is expected to regain profitability, Lee said, aiming to post annual net profit of about NT$400 million.
SynCore reported a net loss of NT$159 million for the first six months of this year, while Sinphar reported net profit of NT$10.34 million, down 71 percent from a year earlier, Sinphar data showed.
Among the rows of vibrators, rubber torsos and leather harnesses at a Chinese sex toys exhibition in Shanghai this weekend, the beginnings of an artificial intelligence (AI)-driven shift in the industry quietly pulsed. China manufactures about 70 percent of the world’s sex toys, most of it the “hardware” on display at the fair — whether that be technicolor tentacled dildos or hyper-realistic personalized silicone dolls. Yet smart toys have been rising in popularity for some time. Many major European and US brands already offer tech-enhanced products that can enable long-distance love, monitor well-being and even bring people one step closer to
Malaysia’s leader yesterday announced plans to build a massive semiconductor design park, aiming to boost the Southeast Asian nation’s role in the global chip industry. A prominent player in the semiconductor industry for decades, Malaysia accounts for an estimated 13 percent of global back-end manufacturing, according to German tech giant Bosch. Now it wants to go beyond production and emerge as a chip design powerhouse too, Malaysian Prime Minister Anwar Ibrahim said. “I am pleased to announce the largest IC (integrated circuit) Design Park in Southeast Asia, that will house world-class anchor tenants and collaborate with global companies such as Arm [Holdings PLC],”
Sales in the retail, and food and beverage sectors last month continued to rise, increasing 0.7 percent and 13.6 percent respectively from a year earlier, setting record highs for the month of March, the Ministry of Economic Affairs said yesterday. Sales in the wholesale sector also grew last month by 4.6 annually, mainly due to the business opportunities for emerging applications related to artificial intelligence (AI) and high-performance computing technologies, the ministry said in a report. The ministry forecast that retail, and food and beverage sales this month would retain their growth momentum as the former would benefit from Tomb Sweeping Day
Thousands of parents in Singapore are furious after a Cordlife Group Ltd (康盛人生集團), a major operator of cord blood banks in Asia, irreparably damaged their children’s samples through improper handling, with some now pursuing legal action. The ongoing case, one of the worst to hit the largely untested industry, has renewed concerns over companies marketing themselves to anxious parents with mostly unproven assurances. This has implications across the region, given Cordlife’s operations in Hong Kong, Macau, Indonesia, the Philippines and India. The parents paid for years to have their infants’ cord blood stored, with the understanding that the stem cells they contained